e-Therapeutics plc is a drug discovery and development company. It pioneered and exploits network pharmacology to evaluate swiftly and accurately how medicines interact with cells in the body. This approach optimises the probability of identifying drug candidates with desirable efficacy and minimal side effects.

Network pharmacology can be applied to many disease areas, and is particularly suited to addressing complex diseases in which current treatment options are few and poor. The company’s current discovery programmes are focused mainly on areas of high unmet medical need, such as neurodegeneration and oncology.

e-Therapeutics’ pipeline has an oral asthma treatment and a novel-mechanism antidepressant in Phase II clinical trials. Regulatory submissions have been made to start Phase III clinical evaluation of both candidates. In addition, the Company has three novel-mechanism antibiotics that kill resistant strains of MRSA and C.difficile, a novel-mechanism cancer chemotherapy, and candidates in atherosclerosis and pain, all of which are being prepared for Phase II clinical trials. The company has out-licensed three candidates for development and commercialisation in India.

e-Therapeutics also provides evaluation services to investors and pharmaceutical companies, analysing drug candidates to determine their indication, efficacy and tolerance properties.